RECRUITING

MOTIV BTK Randomized Controlled Trial

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Pre-market clinical evaluation of the MOTIV Sirolimus-Eluting Bioresorbable Scaffold for the planned treatment of infrapopliteal lesions.

Official Title

A Prospective, Multicenter, Single Blind, Randomized Controlled Trial Evaluating the Safety and Effectiveness of the MOTIV Sirolimus-Eluting Bioresorbable Vascular Scaffold Compared With Plain Balloon Angioplasty for the Treatment of Infrapopliteal Lesions

Quick Facts

Study Start:2022-06-10

Study Completion:2029-03-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05406622

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Subject is at least 18 years of age. 2. Subject presents with symptomatic CLI classified as Rutherford category 4 or 5. 3. Subject agrees to comply with all-protocol specified procedures and follow-up assessments. 4. Subject or subject's legal representative signs an IRB/EC approved informed consent form prior to study participation. 1. Significant stenosis (\>70% diameter stenosis by visual estimate) of one or two native infrapopliteal lesions; if two lesions, each lesion should be in a separate infrapopliteal vessel in the same limb. Unstented restenotic lesions are permitted. 2. Target vessel diameter between 2.5 mm and 3.75 mm and able to be treated with the available device size matrix. 3. Each target lesion is treatable by a maximum of 3 scaffolds, and all target lesions(s) combined must be treatable by a maximum of 4 scaffolds. 4. Total scaffold length among all target lesions must not exceed 120 mm (total sirolimus drug dose of 720 µg). 5. Target lesion(s) must be at least 4 cm above the ankle joint 6. Target lesion(s) are located in an area that may be stented without blocking access to patent main branches. 7. A patent inflow artery from the aorta to the target lesion free from significant stenosis (≥50% diameter stenosis by visual estimate) must be present, as confirmed by angiography. 8. Significant lesions (≥50% diameter stenosis) in inflow arteries must be treated successfully (per physician's assessment) using standard of care treatment prior to enrollment; inflow lesion treatment may be performed during the index procedure. 9. Target vessel(s) reconstitute(s) at or above the ankle or displays normal terminal branching with inline flow to at least one patent (\<50% diameter stenosis by visual assessment) outflow vessel.	1. Subject has severe medical comorbidities or other medical, social or psychological condition that could limit subject's ability to participate in the study or is associated with a life expectancy of less than 1 year. 2. Subject has documented history of stroke within 3 months prior to the procedure. 3. Subject has history of MI, within 30 days prior to the planned index procedure. 4. Subjects with renal failure (estimated Glomerular Filtration Rate \[eGFR\] \< 30 ml/min). 5. Subject has non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis). 6. Subject presents with CLI classified as Rutherford category 6. 7. Subject has acute limb ischemia, defined as symptom onset occurring less than 14 days prior to the index procedure with associated loss of sensation or motor function. 8. Subject had a major amputation that occurred less than one year prior to enrollment and subject is not independently ambulating. 9. Subject has a planned major amputation (of either leg). 10. Subject has had, or currently requires, surgical revascularization in the target vessel. 11. Subject has a planned use of adjunctive primary treatment modalities (e.g., radiation therapy, stents) in below-the-knee vessels; plaque modification technology such as the use of atherectomy, laser or cutting balloons is permitted. 12. Subject has any systemic infection or immunocompromised state. 13. Subject has a coagulation disorder, including hypercoagulability; or the subject has contraindication to anticoagulant or antiplatelet therapy. 14. Subject has a known history of heparin-induced thrombocytopenia (HIT) type II. 15. Subject has known allergy or sensitivity to scaffold or scaffold components. 16. Subject has a known allergy or sensitivity to contrast media that cannot be adequately pre-treated. 17. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period. 18. Subject is currently participating in another investigational drug or device clinical study that has not yet met its primary endpoint. 1. Target lesion(s) with severe calcification (PARC defined). 2. Target lesion(s) will be subjected to significant bending and axial compression. 3. Target lesion(s) located in highly tortuous vessels. 4. Target lesion(s) previously stented (in-stent restenotic lesion). 5. Target vessel(s) has any other significant lesions (≥50% diameter stenosis by visual assessment) that is not a target lesion. 6. Target vessel previously treated within 3 months prior to index procedure 7. Angiographic evidence of thromboembolism in target limb 8. Inflow-limiting arterial stenoses are unsuccessfully treated or left untreated

Inclusion Criteria

Exclusion Criteria

1. Subject is at least 18 years of age.
2. Subject presents with symptomatic CLI classified as Rutherford category 4 or 5.
3. Subject agrees to comply with all-protocol specified procedures and follow-up assessments.
4. Subject or subject's legal representative signs an IRB/EC approved informed consent form prior to study participation.
1. Significant stenosis (\>70% diameter stenosis by visual estimate) of one or two native infrapopliteal lesions; if two lesions, each lesion should be in a separate infrapopliteal vessel in the same limb. Unstented restenotic lesions are permitted.
2. Target vessel diameter between 2.5 mm and 3.75 mm and able to be treated with the available device size matrix.
3. Each target lesion is treatable by a maximum of 3 scaffolds, and all target lesions(s) combined must be treatable by a maximum of 4 scaffolds.
4. Total scaffold length among all target lesions must not exceed 120 mm (total sirolimus drug dose of 720 µg).
5. Target lesion(s) must be at least 4 cm above the ankle joint
6. Target lesion(s) are located in an area that may be stented without blocking access to patent main branches.
7. A patent inflow artery from the aorta to the target lesion free from significant stenosis (≥50% diameter stenosis by visual estimate) must be present, as confirmed by angiography.
8. Significant lesions (≥50% diameter stenosis) in inflow arteries must be treated successfully (per physician's assessment) using standard of care treatment prior to enrollment; inflow lesion treatment may be performed during the index procedure.
9. Target vessel(s) reconstitute(s) at or above the ankle or displays normal terminal branching with inline flow to at least one patent (\<50% diameter stenosis by visual assessment) outflow vessel.

1. Subject has severe medical comorbidities or other medical, social or psychological condition that could limit subject's ability to participate in the study or is associated with a life expectancy of less than 1 year.
2. Subject has documented history of stroke within 3 months prior to the procedure.
3. Subject has history of MI, within 30 days prior to the planned index procedure.
4. Subjects with renal failure (estimated Glomerular Filtration Rate \[eGFR\] \< 30 ml/min).
5. Subject has non-atherosclerotic disease resulting in occlusion (e.g., embolism, Buerger's disease, vasculitis).
6. Subject presents with CLI classified as Rutherford category 6.
7. Subject has acute limb ischemia, defined as symptom onset occurring less than 14 days prior to the index procedure with associated loss of sensation or motor function.
8. Subject had a major amputation that occurred less than one year prior to enrollment and subject is not independently ambulating.
9. Subject has a planned major amputation (of either leg).
10. Subject has had, or currently requires, surgical revascularization in the target vessel.
11. Subject has a planned use of adjunctive primary treatment modalities (e.g., radiation therapy, stents) in below-the-knee vessels; plaque modification technology such as the use of atherectomy, laser or cutting balloons is permitted.
12. Subject has any systemic infection or immunocompromised state.
13. Subject has a coagulation disorder, including hypercoagulability; or the subject has contraindication to anticoagulant or antiplatelet therapy.
14. Subject has a known history of heparin-induced thrombocytopenia (HIT) type II.
15. Subject has known allergy or sensitivity to scaffold or scaffold components.
16. Subject has a known allergy or sensitivity to contrast media that cannot be adequately pre-treated.
17. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period.
18. Subject is currently participating in another investigational drug or device clinical study that has not yet met its primary endpoint.
1. Target lesion(s) with severe calcification (PARC defined).
2. Target lesion(s) will be subjected to significant bending and axial compression.
3. Target lesion(s) located in highly tortuous vessels.
4. Target lesion(s) previously stented (in-stent restenotic lesion).
5. Target vessel(s) has any other significant lesions (≥50% diameter stenosis by visual assessment) that is not a target lesion.
6. Target vessel previously treated within 3 months prior to index procedure
7. Angiographic evidence of thromboembolism in target limb
8. Inflow-limiting arterial stenoses are unsuccessfully treated or left untreated

Contacts and Locations

Study Contact

Danielle Gram

CONTACT

+1 (858) 966-3021

dgram@revamedical.com

Jeff Anderson

CONTACT

+1 (858) 966-3038

janderson@revamedical.com

Principal Investigator

Ehrin Armstrong, MD

PRINCIPAL_INVESTIGATOR

Adventist Health

Andrej Schmidt, PD Dr.

PRINCIPAL_INVESTIGATOR

University Leipzig

Study Locations (Sites)

Adventist Health

Saint Helena, California, 94574

United States

UnityPoint Health Trinity Bettendorf Hospital

Bettendorf, Iowa, 52722

United States

Cardiovascular Medicine PC

Davenport, Iowa, 52803

United States

Collaborators and Investigators

Sponsor: REVA Medical, Inc.

Ehrin Armstrong, MD, PRINCIPAL_INVESTIGATOR, Adventist Health
Andrej Schmidt, PD Dr., PRINCIPAL_INVESTIGATOR, University Leipzig

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-06-10

Study Completion Date2029-03-31

Study Record Updates

Study Start Date2022-06-10

Study Completion Date2029-03-31

Terms related to this study

Additional Relevant MeSH Terms

Critical Limb Ischemia